Certara, Inc.

Certara, Inc. is the company identified by ticker CERT on this research page. Use the overview to review the business, financial results, valuation and related news.

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.

Check the CERT quote and chart on the overview and Chart tabs. Confirm the quote time, currency and trading session before comparing prices; a research update time is not a quote timestamp.

The Forecast tab shows available analyst price targets for CERT. Analyst targets are separate from BTI scores and valuation estimates. Missing targets are unavailable, and forecasts do not guarantee returns.

Review Certara, Inc.'s investor-relations announcements for declared dividends, ex-dividend dates and payment dates. A missing or zero yield in a data feed alone does not establish the company's dividend policy.

Check the Earnings tab for available dates and reported results, then confirm the next announcement with Certara, Inc.'s investor-relations calendar. Estimated dates may change.

Compare CERT's Valuation and Financials tabs, including cash flow, growth assumptions and valuation multiples. BTI estimates depend on their inputs and are different from analyst price targets.

Review Certara, Inc.'s latest company filings for business-specific risks, alongside debt, profitability, competition and valuation. A BTI score summarizes research and is not a personalized investment recommendation.